ZA202000208B - 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof - Google Patents
3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereofInfo
- Publication number
- ZA202000208B ZA202000208B ZA2020/00208A ZA202000208A ZA202000208B ZA 202000208 B ZA202000208 B ZA 202000208B ZA 2020/00208 A ZA2020/00208 A ZA 2020/00208A ZA 202000208 A ZA202000208 A ZA 202000208A ZA 202000208 B ZA202000208 B ZA 202000208B
- Authority
- ZA
- South Africa
- Prior art keywords
- oxoisoindolin
- piperidine
- dione derivatives
- dione
- derivatives
- Prior art date
Links
- WENKGSGGXGQHSH-UHFFFAOYSA-N 3-(3-oxo-1h-isoindol-2-yl)piperidine-2,6-dione Chemical class C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O WENKGSGGXGQHSH-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762549225P | 2017-08-23 | 2017-08-23 | |
| PCT/IB2018/056400 WO2019038717A1 (en) | 2017-08-23 | 2018-08-23 | 3- (1-OXOISOINDOLIN-2-YL) PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202000208B true ZA202000208B (en) | 2021-07-28 |
Family
ID=63638171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2020/00208A ZA202000208B (en) | 2017-08-23 | 2020-01-13 | 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
Country Status (38)
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| EP3454856B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| TWI793151B (zh) | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
| WO2019199816A1 (en) * | 2018-04-13 | 2019-10-17 | Arvinas Operations, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| AR116109A1 (es) * | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| EP3820573B1 (en) * | 2018-07-10 | 2023-08-09 | Novartis AG | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases |
| WO2020117759A1 (en) | 2018-12-03 | 2020-06-11 | Dana-Farber Cancer Institute, Inc. | Small molecule degraders of helios and methods of use |
| US20240245670A1 (en) * | 2018-12-20 | 2024-07-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| EP3924055B1 (en) * | 2019-02-15 | 2024-04-03 | Novartis AG | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| EP3924054B1 (en) * | 2019-02-15 | 2025-04-02 | Novartis AG | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| EA202192738A1 (ru) | 2019-04-12 | 2022-03-17 | С4 Терапьютикс, Инк. | Трициклические соединения, обеспечивающие разрушение белка ikaros и белка aiolos |
| US20220251152A1 (en) | 2019-04-24 | 2022-08-11 | Novartis Ag | Compositions and methods for selective protein degradation |
| MX2021014443A (es) | 2019-05-31 | 2022-01-06 | Ikena Oncology Inc | Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos. |
| AU2020282759A1 (en) | 2019-05-31 | 2021-12-23 | Ikena Oncology, Inc. | TEAD inhibitors and uses thereof |
| AU2020374957A1 (en) * | 2019-10-30 | 2022-04-28 | Dana-Farber Cancer Institute, Inc. | Small molecule degraders of Helios and methods of use |
| CN110862395B (zh) * | 2019-11-13 | 2020-09-29 | 株洲千金药业股份有限公司 | 一种制备他达拉非重要杂质的原料化合物的制备方法 |
| KR20220103753A (ko) * | 2019-11-19 | 2022-07-22 | 브리스톨-마이어스 스큅 컴퍼니 | 헬리오스 단백질의 억제제로서 유용한 화합물 |
| TW202140441A (zh) * | 2020-03-23 | 2021-11-01 | 美商必治妥美雅史谷比公司 | 經取代之側氧基異吲哚啉化合物 |
| US20230203022A1 (en) * | 2020-04-30 | 2023-06-29 | Shanghaitech University | Heterocycle and glutarimide skeleton-based compound and applications thereof |
| CA3182346A1 (en) | 2020-06-23 | 2021-12-30 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| WO2022007903A1 (zh) * | 2020-07-09 | 2022-01-13 | 四川海思科制药有限公司 | 一种能够抑制并降解雄激素受体的化合物及其药物组合物和药学上的应用 |
| AU2021319847A1 (en) * | 2020-08-03 | 2023-03-02 | Captor Therapeutics S.A. | Low molecular weight protein degraders and their applications |
| CN116134027B (zh) * | 2020-08-03 | 2025-01-24 | 诺华股份有限公司 | 杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
| EP4217352A4 (en) | 2020-09-23 | 2024-04-10 | St. Jude Children's Research Hospital, Inc. | Substituted n-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)arylsulfonamide analogs as modulators of cereblon protein |
| EP4225749A4 (en) * | 2020-10-07 | 2025-05-14 | Cullgen (Shanghai), Inc. | Compounds and methods of treating cancers |
| MX2023004374A (es) * | 2020-10-14 | 2023-07-06 | C4 Therapeutics Inc | Ligandos tricíclicos para la degradación de la familia ikaros 2 o la familia ikaros 4. |
| CN116669769A (zh) * | 2020-10-16 | 2023-08-29 | 达纳－法伯癌症研究所公司 | Helios的哌啶基小分子降解剂和使用方法 |
| WO2022081976A1 (en) * | 2020-10-16 | 2022-04-21 | Dana-Farber Cancer Institute, Inc. | Piperidinyl small molecule degraders of helios and methods of use |
| WO2022120355A1 (en) * | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead degraders and uses thereof |
| UY39671A (es) * | 2021-03-15 | 2022-10-31 | Novartis Ag | Derivados de pirazolopiridina y sus usos. |
| AU2022253242A1 (en) | 2021-04-06 | 2023-11-23 | Bristol-Myers Squibb Company | Pyridinyl substituted oxoisoindoline compounds |
| JP2024517772A (ja) * | 2021-04-29 | 2024-04-23 | ネオモルフ インコーポレイテッド | 置換された２－（２，６－ジオキソピペリジン－３－イル）－５－（１－ピペリジン－４－イル）イソインドリン－１，３－ジオン誘導体及びその使用 |
| CA3209633A1 (en) * | 2021-04-29 | 2022-11-03 | Tinghu Zhang | Phthalimido cereblon complex binders and transcription factor degraders and methods of use |
| KR20240035820A (ko) | 2021-07-09 | 2024-03-18 | 플렉시움 인코포레이티드 | Ikzf2를 조절하는 아릴 화합물 및 약학 조성물 |
| AR126718A1 (es) | 2021-08-06 | 2023-11-08 | Celgene Corp | Composiciones y métodos para la degradación selectiva de proteínas diseñadas por ingeniería |
| CN118475567A (zh) * | 2021-08-11 | 2024-08-09 | 西藏海思科制药有限公司 | 一种杂环衍生物及其组合物和药学上的应用 |
| CN116003418A (zh) * | 2021-10-22 | 2023-04-25 | 标新生物医药科技(上海)有限公司 | Crbn e3连接酶配体化合物、基于该配体化合物开发的蛋白降解剂及它们的应用 |
| KR20240091056A (ko) | 2021-10-28 | 2024-06-21 | 길리애드 사이언시즈, 인코포레이티드 | 피리디진-3(2h)-온 유도체 |
| WO2023077030A1 (en) | 2021-10-29 | 2023-05-04 | Gilead Sciences, Inc. | Cd73 compounds |
| EP4452414A2 (en) | 2021-12-22 | 2024-10-30 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| JP2024545193A (ja) * | 2021-12-22 | 2024-12-05 | ギリアード サイエンシーズ， インコーポレイテッド | Ｉｋａｒｏｓジンクフィンガーファミリー分解剤及びその使用 |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| CN116640122A (zh) * | 2022-02-16 | 2023-08-25 | 苏州国匡医药科技有限公司 | Ikzf2降解剂及包含其的药物组合物和用途 |
| US12358887B2 (en) | 2022-03-17 | 2025-07-15 | Gilead Sciences, Inc. | IKAROS Zinc Finger Family degraders and uses thereof |
| US20250215012A1 (en) * | 2022-03-25 | 2025-07-03 | Regents Of The University Of Michigan | Ikzf2 degraders and uses thereof |
| CN119585252A (zh) * | 2022-03-25 | 2025-03-07 | 翁科皮亚治疗公司和Sk生命科学实验室 | 作为ikzf2降解剂的含二环杂芳基的化合物 |
| WO2023201012A1 (en) * | 2022-04-15 | 2023-10-19 | Regents Of The University Of Michigan | Ikzf2 degraders and uses thereof |
| CN119487038A (zh) | 2022-04-21 | 2025-02-18 | 吉利德科学公司 | Kras g12d调节化合物 |
| WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
| CN117881668A (zh) * | 2022-08-10 | 2024-04-12 | 标新生物医药科技(上海)有限公司 | 基于异吲哚啉取代戊二酰亚胺骨架的化合物及其应用 |
| WO2024059107A1 (en) * | 2022-09-14 | 2024-03-21 | President And Fellows Of Harvard College | Ikzf2 and ck1-alpha degrading compounds and uses thereof |
| JP2025541840A (ja) * | 2022-12-07 | 2025-12-23 | ハンジョウ グルバイオ ファーマシューティカル カンパニー リミテッド | 固体分散体、その製造方法と使用 |
| EP4638436A1 (en) | 2022-12-22 | 2025-10-29 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| EP4660193A1 (en) | 2023-01-31 | 2025-12-10 | Korea Research Institute of Chemical Technology | Indole compound decomposing ikzf2, and use thereof |
| WO2024215754A1 (en) | 2023-04-11 | 2024-10-17 | Gilead Sciences, Inc. | Kras modulating compounds |
| CN121079300A (zh) | 2023-04-21 | 2025-12-05 | 吉利德科学公司 | Prmt5抑制剂及其用途 |
| US20250042922A1 (en) | 2023-06-30 | 2025-02-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| US20250066328A1 (en) | 2023-07-26 | 2025-02-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025024811A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025054530A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| WO2025054347A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2025067466A1 (zh) * | 2023-09-28 | 2025-04-03 | 杭州多域生物技术有限公司 | 一种杂环化合物、其组合物及应用 |
| TW202530195A (zh) * | 2023-10-06 | 2025-08-01 | 美商德爾菲亞治療股份有限公司 | 化合物、其醫藥組合物及其使用方法 |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025113643A1 (en) | 2023-12-01 | 2025-06-05 | Gilead Sciences Inc. | Anti-fap-light fusion protein and use thereof |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025245178A1 (en) * | 2024-05-21 | 2025-11-27 | Innovo Therapeutics, Inc. | Pak4, cstf2, or cstf2t protein degraders, pharmaceutical compositions, and therapeutic applications |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5114946A (en) | 1987-06-12 | 1992-05-19 | American Cyanamid Company | Transdermal delivery of pharmaceuticals |
| US4818541A (en) | 1987-08-19 | 1989-04-04 | Schering Corporation | Transdermal delivery of enantiomers of phenylpropanolamine |
| US7196170B2 (en) | 1992-09-14 | 2007-03-27 | The General Hospital Corporation | Aiolos, Helios, Daedalos and Ikaros: genes, polypeptides, regulatory elements and uses thereof |
| US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
| CZ302378B6 (cs) | 1996-07-24 | 2011-04-20 | Celgene Corporation | Optický izomer (S)-1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindolin a farmaceutická kompozice s jeho obsahem |
| WO2002044372A2 (en) | 2000-12-01 | 2002-06-06 | Parker Hughes Institute | Nucleotide and protein sequence of helios 3 and methods of use |
| EP1396493A4 (en) | 2001-04-26 | 2005-08-03 | Ajinomoto Kk | HETEROCYCLIC COMPOUNDS |
| CA2457319C (en) | 2001-08-06 | 2011-07-05 | The Children's Medical Center Corporation | Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs |
| US20050203142A1 (en) | 2002-10-24 | 2005-09-15 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
| US20040087558A1 (en) | 2002-10-24 | 2004-05-06 | Zeldis Jerome B. | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
| US7612096B2 (en) | 2003-10-23 | 2009-11-03 | Celgene Corporation | Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline |
| US20070161696A1 (en) | 2004-04-23 | 2007-07-12 | Zeldis Jerome B | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
| KR20070057907A (ko) * | 2004-09-03 | 2007-06-07 | 셀진 코포레이션 | 치환된 2-(2,6-디옥소피페리딘-3-일)-1-옥소이소인돌린의제조 방법 |
| JP4731867B2 (ja) | 2004-10-01 | 2011-07-27 | 国立大学法人三重大学 | Ｃｄ８陽性の細胞傷害性ｔリンパ球の誘導方法 |
| WO2006060507A2 (en) | 2004-12-01 | 2006-06-08 | Celgene Corporation | Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders |
| ATE481504T1 (de) | 2004-12-10 | 2010-10-15 | Siemens Healthcare Diagnostics | Für die vorhersage des ansprechens maligner neoplasie auf eine auf taxan beruhende medizinische behandlung geeignete genetische veränderung |
| WO2007067500A2 (en) | 2005-12-05 | 2007-06-14 | Genomic Health, Inc. | Predictors of patient response to treatment with egfr inhibitors |
| US9598669B2 (en) | 2005-12-29 | 2017-03-21 | Anthrogenesis Corporation | Composition for collecting placental stem cells and methods of using the composition |
| WO2007111904A2 (en) | 2006-03-22 | 2007-10-04 | Vertex Pharmaceuticals Incorporated | C-met protein kinase inhibitors for the treatment of proliferative disorders |
| US20070269827A1 (en) | 2006-05-18 | 2007-11-22 | Oklahoma Medical Research Foundation | Predicting and Diagnosing Patients With Autoimmune Disease |
| KR101342035B1 (ko) | 2006-06-20 | 2013-12-16 | 한국과학기술연구원 | 신장독성 및 부작용 유발 약물 검색용 바이오마커 및 이를이용한 신장독성 및 부작용 유발 약물 검색 방법 |
| US8877780B2 (en) | 2006-08-30 | 2014-11-04 | Celgene Corporation | 5-substituted isoindoline compounds |
| JP2009092508A (ja) | 2007-10-09 | 2009-04-30 | Norihiro Nishimoto | リウマチ治療剤の効果の予測方法 |
| WO2009068621A1 (en) | 2007-11-30 | 2009-06-04 | Glaxosmithkline Biologicals S.A. | Method for classifying cancer patients as responder or non-responder to immunotherapy |
| KR100957051B1 (ko) | 2007-12-28 | 2010-05-13 | 한국과학기술연구원 | 니트로푸란토인 처리에 따른, 폐독성 유발 약물 검색용마커유전자 및 이를 이용한 검색 방법 |
| GB2456390A (en) | 2008-01-15 | 2009-07-22 | Glaxo Group Ltd | Bipolar disorder treatments |
| WO2009094592A2 (en) | 2008-01-23 | 2009-07-30 | Perlegen Sciences, Inc. | Genetic basis of alzheimer's disease and diagnosis and treatment thereof |
| US20090307180A1 (en) | 2008-03-19 | 2009-12-10 | Brandon Colby | Genetic analysis |
| US20110229498A1 (en) | 2008-05-08 | 2011-09-22 | The Johns Hopkins University | Compositions and methods for modulating an immune response |
| EP2177615A1 (en) | 2008-10-10 | 2010-04-21 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases |
| US20100204265A1 (en) | 2009-02-09 | 2010-08-12 | Genelabs Technologies, Inc. | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections |
| US9212177B2 (en) | 2009-08-05 | 2015-12-15 | Versitech Limited | Antiviral compounds and methods of making and using thereof |
| BR112012002331A2 (pt) | 2009-08-05 | 2019-09-24 | Versitech Ltd | composição antiviral, composição farmacêutica e uso de quantidade efetiva de composição farmacêutica |
| CA2778005A1 (en) | 2009-10-26 | 2011-05-12 | Abbott Laboratories | Detection of chromosomal abnormalities associated with prognosis of non small cell lung cancer |
| DK2569446T3 (en) | 2010-05-12 | 2018-10-29 | Steven E Schutzer | DIAGNOSTIC MARKERS FOR NEUROPsychiatric Disease |
| US20120142701A1 (en) | 2010-05-28 | 2012-06-07 | The University Of Hong Kong | Compounds and methods for the treatment of proliferative diseases |
| WO2011151941A1 (ja) | 2010-06-04 | 2011-12-08 | 国立大学法人東京大学 | 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物 |
| WO2012021867A2 (en) | 2010-08-13 | 2012-02-16 | The Johns Hopkins University | A comprehensive methylome map of myeloid and lymphoid commitment from hematopoietic progenitors |
| AU2011317211B2 (en) | 2010-10-22 | 2015-04-16 | Dana-Farber Cancer Institute, Inc. | Discovery of regulatory T cells programmed to suppress an immune response |
| JP6001060B2 (ja) | 2011-06-06 | 2016-10-05 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | 筋萎縮を阻害するための方法 |
| EP2723362A1 (en) | 2011-06-21 | 2014-04-30 | Innate Pharma | NKp46-MEDIATED NK CELL TUNING |
| CN103782173B (zh) | 2011-07-01 | 2018-07-13 | 贝克曼考尔特公司 | 调节t细胞和识别、获得、以及用于治疗基于免疫的紊乱的方法 |
| CN103797120B (zh) | 2011-09-16 | 2017-04-12 | 上海长海医院 | 前列腺癌的生物学标志物、治疗靶点及其用途 |
| JP6306507B2 (ja) | 2011-12-01 | 2018-04-18 | 国立大学法人 東京大学 | 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌 |
| US9481866B2 (en) | 2011-12-16 | 2016-11-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing T cell populations enriched for stable regulatory T-cells |
| WO2013098797A2 (en) | 2011-12-31 | 2013-07-04 | Kuriakose Moni Abraham | Diagnostic tests for predicting prognosis, recurrence, resistance or sensitivity to therapy and metastatic status in cancer |
| JP6422344B2 (ja) | 2012-03-02 | 2018-11-14 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 同種抗原反応性の制御性ｔ細胞を増大させる方法 |
| GB201207297D0 (en) | 2012-04-26 | 2012-06-06 | Senzagen Ab | Analytical methods and arrays for use in the same |
| GB201213571D0 (en) | 2012-07-31 | 2012-09-12 | Univ Leuven Kath | Growth factor cocktail to enhnce osteogenic differentiayion of mesenchymal |
| EP2682750A1 (en) | 2012-07-02 | 2014-01-08 | Sotio a.s. | In vitro method for the diagnosis and surveillance of cancer |
| EP2903692B1 (en) | 2012-10-08 | 2019-12-25 | St. Jude Children's Research Hospital | Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis |
| WO2014122467A1 (en) | 2013-02-06 | 2014-08-14 | Loxbridge Research Llp | Systems and methods for early disease detection and real-time disease monitoring |
| WO2014153069A2 (en) | 2013-03-14 | 2014-09-25 | Children's Medical Center Corporation | Compositions and methods for reprogramming hematopoietic stem cell lineages |
| BR112015022490A2 (pt) | 2013-03-15 | 2017-07-18 | Veracyte Inc | métodos e composições para classificação de amostras |
| US20160122821A1 (en) | 2013-06-10 | 2016-05-05 | Suregene, Llc | Genetic markers of antipsychotic response |
| GB2532672A (en) | 2013-09-09 | 2016-05-25 | Scripps Research Inst | Methods and systems for analysis of organ transplantation |
| WO2015050875A1 (en) | 2013-10-01 | 2015-04-09 | The Regents Of The University Of California | Endometriosis classifier |
| UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| WO2015109212A1 (en) | 2014-01-17 | 2015-07-23 | Pfizer Inc. | Anti-il-2 antibodies and compositions and uses thereof |
| WO2015107196A1 (en) | 2014-01-20 | 2015-07-23 | Institut Curie | Use of thalidomide or analogs thereof for preventing neurologic disorders induced by brain irradiation |
| US20160058872A1 (en) * | 2014-04-14 | 2016-03-03 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| KR20250127179A (ko) * | 2014-04-14 | 2025-08-26 | 아비나스 오퍼레이션스, 인코포레이티드 | 단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법 |
| EP4112738B1 (en) | 2014-12-05 | 2024-07-24 | Foundation Medicine, Inc. | Multigene analysis of tumor samples |
| EP3034620A1 (en) | 2014-12-17 | 2016-06-22 | Diaxonhit | Compositions and methods for diagnosing thyroid cancer |
| WO2016103269A1 (en) | 2014-12-23 | 2016-06-30 | Ramot At Tel-Aviv University Ltd. | Populations of neural progenitor cells and methods of producing and using same |
| CA2973873A1 (en) | 2015-01-20 | 2016-07-28 | Merial, Inc. | Anthelmintic compounds, compositions and method of using thereof |
| EP3050570A1 (en) | 2015-01-31 | 2016-08-03 | Neurovision Pharma GmbH | Pharmaceutical composition consisting of a combination of G-CSF with GM-CSF |
| WO2016140974A1 (en) | 2015-03-01 | 2016-09-09 | Novena Therapeutics Inc. | Process for measuring tumor response to an initial oncology treatment |
| CA2986141C (en) | 2015-05-22 | 2020-07-28 | Biotheryx, Inc. | Compounds targeting proteins, compositions, methods, and uses thereof |
| EP3304076A4 (en) | 2015-06-02 | 2018-12-19 | Celgene Corporation | Methods for determining drug efficacy for treatment of cancer using ratios of cereblon associated proteins |
| EP3302548A4 (en) | 2015-06-03 | 2019-01-02 | Dana Farber Cancer Institute, Inc. | Methods to induce conversion of regulatory t cells into effector t cells for cancer immunotherapy |
| EP3310367A4 (en) | 2015-06-22 | 2019-02-20 | President and Fellows of Harvard College | INDUCTION OF LAMINA-PROPRIA-REGULATORY T-CELLS |
| WO2017042337A1 (en) | 2015-09-09 | 2017-03-16 | Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmhotz-Gemeinschaft | Short-chain fatty acids for use in the treatment of cardiovascular disease |
| US20180250369A1 (en) | 2015-09-11 | 2018-09-06 | Ventria Bioscience, Inc. | Lactoferrin compositions and methods for modulation of t cell subtypes and treatment of autoimmune diseases |
| WO2017058881A1 (en) | 2015-09-28 | 2017-04-06 | The Trustees Of Columbia University In The City Of New York | Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma |
| KR102838444B1 (ko) | 2015-09-30 | 2025-07-24 | 더 유니버시티 코트 오브 더 유니버시티 오브 애버딘 | 탈리도마이드 유사체 및 사용 방법 |
| WO2017075465A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3 |
| WO2017075451A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1 |
| EP3368689B1 (en) | 2015-10-28 | 2020-06-17 | The Broad Institute, Inc. | Composition for modulating immune responses by use of immune cell gene signature |
| WO2017095525A1 (en) | 2015-12-04 | 2017-06-08 | David Scott | Antigen-specific t cells for inducing immune tolerance |
| WO2017161001A1 (en) | 2016-03-15 | 2017-09-21 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion |
| US10759808B2 (en) | 2016-04-06 | 2020-09-01 | The Regents Of The University Of Michigan | Monofunctional intermediates for ligand-dependent target protein degradation |
| US11078247B2 (en) | 2016-05-04 | 2021-08-03 | Curevac Ag | RNA encoding a therapeutic protein |
| WO2017197056A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Bromodomain targeting degronimers for target protein degradation |
| WO2017197051A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Amine-linked c3-glutarimide degronimers for target protein degradation |
| HUE061847T2 (hu) | 2016-10-11 | 2023-08-28 | Arvinas Operations Inc | Androgén receptor célzott degradálására alkalmas vegyületek és eljárások |
| WO2018118598A1 (en) | 2016-12-23 | 2018-06-28 | Arvinas, Inc. | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides |
| CN110741004B (zh) | 2016-12-23 | 2023-10-17 | 阿尔维纳斯运营股份有限公司 | 用于迅速加速性纤维肉瘤多肽的靶向降解的化合物和方法 |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| AU2018211975B2 (en) | 2017-01-26 | 2022-05-26 | Arvinas Operations, Inc. | Modulators of estrogen receptor proteolysis and associated methods of use |
| CN106932576A (zh) | 2017-03-22 | 2017-07-07 | 山东大学深圳研究院 | 一种人调节性t细胞的免疫抑制功能的检测方法 |
| TWI793151B (zh) | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
-
2018
- 2018-08-21 TW TW107129068A patent/TWI793151B/zh not_active IP Right Cessation
- 2018-08-22 UY UY0001037854A patent/UY37854A/es not_active Application Discontinuation
- 2018-08-22 AR ARP180102390 patent/AR112529A1/es not_active Application Discontinuation
- 2018-08-22 US US16/108,713 patent/US10414755B2/en active Active
- 2018-08-23 MX MX2020002060A patent/MX2020002060A/es unknown
- 2018-08-23 HU HUE18772885A patent/HUE061895T2/hu unknown
- 2018-08-23 JO JOP/2020/0042A patent/JOP20200042A1/ar unknown
- 2018-08-23 CR CR20200081A patent/CR20200081A/es unknown
- 2018-08-23 AU AU2018319577A patent/AU2018319577B2/en not_active Ceased
- 2018-08-23 HR HRP20230244TT patent/HRP20230244T1/hr unknown
- 2018-08-23 CU CU2020000014A patent/CU20200014A7/es unknown
- 2018-08-23 EP EP18772885.2A patent/EP3672949B9/en active Active
- 2018-08-23 FI FIEP18772885.2T patent/FI3672949T3/fi active
- 2018-08-23 JP JP2020510565A patent/JP7386787B2/ja active Active
- 2018-08-23 LT LTEPPCT/IB2018/056400T patent/LT3672949T/lt unknown
- 2018-08-23 EA EA202090553A patent/EA202090553A1/ru unknown
- 2018-08-23 PL PL18772885.2T patent/PL3672949T3/pl unknown
- 2018-08-23 CN CN201880053653.2A patent/CN111051298B/zh active Active
- 2018-08-23 WO PCT/IB2018/056400 patent/WO2019038717A1/en not_active Ceased
- 2018-08-23 SI SI201830871T patent/SI3672949T1/sl unknown
- 2018-08-23 MA MA49952A patent/MA49952B1/fr unknown
- 2018-08-23 ES ES18772885T patent/ES2940448T3/es active Active
- 2018-08-23 DK DK18772885.2T patent/DK3672949T5/da active
- 2018-08-23 PT PT187728852T patent/PT3672949T/pt unknown
- 2018-08-23 PE PE2020000271A patent/PE20200796A1/es unknown
- 2018-08-23 SG SG11202000490PA patent/SG11202000490PA/en unknown
- 2018-08-23 BR BR112020003373-1A patent/BR112020003373B1/pt not_active IP Right Cessation
- 2018-08-23 CA CA3072694A patent/CA3072694A1/en active Pending
- 2018-08-23 RS RS20230203A patent/RS64058B9/sr unknown
- 2018-08-23 EP EP22213789.5A patent/EP4183782A1/en not_active Withdrawn
- 2018-08-23 KR KR1020207007884A patent/KR20200044038A/ko not_active Ceased
-
2019
- 2019-08-05 US US16/532,106 patent/US10640489B2/en active Active
- 2019-08-05 US US16/532,118 patent/US10647701B2/en not_active Expired - Fee Related
-
2020
- 2020-01-13 ZA ZA2020/00208A patent/ZA202000208B/en unknown
- 2020-01-17 PH PH12020500125A patent/PH12020500125A1/en unknown
- 2020-02-18 IL IL272748A patent/IL272748B2/en unknown
- 2020-02-20 CO CONC2020/0001860A patent/CO2020001860A2/es unknown
- 2020-02-20 EC ECSENADI202013248A patent/ECSP20013248A/es unknown
- 2020-02-20 CL CL2020000427A patent/CL2020000427A1/es unknown
- 2020-02-20 SA SA520411325A patent/SA520411325B1/ar unknown
- 2020-02-20 DO DO2020000037A patent/DOP2020000037A/es unknown
- 2020-03-31 US US16/835,938 patent/US11053218B2/en not_active Expired - Fee Related
- 2020-11-26 AU AU2020277231A patent/AU2020277231A1/en not_active Abandoned
-
2021
- 2021-06-09 US US17/343,016 patent/US20210309638A1/en not_active Abandoned
-
2022
- 2022-09-13 AU AU2022231670A patent/AU2022231670A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272748A (en) | 3-(1-Oxoisoindolin-2-YL)piperidine-2,6-dione derivatives and their use | |
| IL283148A (en) | Dosage regimen and pharmaceutical combination containing 3-(1-oxoisoindoline-2-YL)piperidine-2,6-dione derivatives | |
| IL278877A (en) | Amino-pyrazinecarboxamide compounds, conjugates and their uses | |
| HUE066348T2 (hu) | Heterociklusos flavon-származékok és az ezekhez kapcsolódó készítmények és eljárások | |
| EP3640248B8 (en) | Aminopyrimidine derivatives, preparation method therefor and use thereof | |
| IL273571A (en) | Azterion derivatives and their uses | |
| IL260488B (en) | History of 8-amino-2-oxo-3,1-diaza-spiro-[5.4]-decane | |
| IL260495B (en) | History of 3-(carboxyethyl)-8-amino-2-oxo-3,1-diaza-spiro-[5.4]-decane | |
| IL260497B (en) | History of 3-(Carboxymethyl)-8-amino-2-oxo-3,1-diaza-spiro-[5.4]-decane | |
| IL261643B (en) | Piperidine derivatives, their preparation and use | |
| EP3166945A4 (en) | Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof | |
| IL248773B (en) | History -6,1-Naphthyridine-5,4-Dione and pharmaceutical preparations containing them | |
| GB2590189B (en) | Lycorine derivative, and pharmaceutical composition and use thereof | |
| DK3604303T3 (da) | Hidtil ukendt pyrrolopyridinderivat, fremgangsmåde til fremstilling heraf og anvendelse deraf | |
| IL259597A (en) | Cycling therapy using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione | |
| IL257666A (en) | Pharmaceutical compositions comprising 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione | |
| EP3199526A4 (en) | Intermediate for use in synthesizing paroxetine, preparation method for the intermediate, and uses thereof | |
| PL3386988T3 (pl) | Nowe pochodne dihydropiranopirymidynonu i ich zastosowanie | |
| EP3219311A4 (en) | Pharmaceutical composition comprising dabigatran etexilate, and preparation method, solid preparation and use thereof | |
| IL262597B (en) | Piperidinyl derivatives, their preparation and use | |
| GB2562202B (en) | Oral rehydration device | |
| HK40057253A (en) | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives | |
| EP3166946A4 (en) | Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof | |
| ZA201904654B (en) | Benzimidazole derivatives, preparation methods and uses thereof | |
| HUE064420T2 (hu) | Dipeptidil-ketoamid-meta-metoxifenil-származékok és alkalmazásuk |